COMBI Stock Overview
CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
CombiGene AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr3.72 |
| 52 Week High | kr8.10 |
| 52 Week Low | kr2.00 |
| Beta | 1.3 |
| 1 Month Change | -1.59% |
| 3 Month Change | 23.38% |
| 1 Year Change | -43.89% |
| 3 Year Change | -56.13% |
| 5 Year Change | -85.69% |
| Change since IPO | -97.92% |
Recent News & Updates
Shareholder Returns
| COMBI | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -3.4% | -0.8% | -1.6% |
| 1Y | -43.9% | -5.1% | 7.8% |
Return vs Industry: COMBI underperformed the Swedish Biotechs industry which returned -5.1% over the past year.
Return vs Market: COMBI underperformed the Swedish Market which returned 7.8% over the past year.
Price Volatility
| COMBI volatility | |
|---|---|
| COMBI Average Weekly Movement | 8.0% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 12.8% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: COMBI has not had significant price volatility in the past 3 months.
Volatility Over Time: COMBI's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 11 | Peter Ekolind | www.combigene.com |
CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two gene therapy candidates, including CG01, which is in preclinical studies for the treatment of epilepsy and biodistribution and toxicology studies; and CGT2 for the treatment of lipodystrophy. The company has a licensing and collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions; and with Spark Therapeutics to develop adeno-associated virus (AAV) based gene therapies.
CombiGene AB (publ) Fundamentals Summary
| COMBI fundamental statistics | |
|---|---|
| Market cap | kr73.66m |
| Earnings (TTM) | -kr35.66m |
| Revenue (TTM) | kr7.01m |
10.5x
P/S Ratio-2.1x
P/E RatioIs COMBI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| COMBI income statement (TTM) | |
|---|---|
| Revenue | kr7.01m |
| Cost of Revenue | kr26.84m |
| Gross Profit | -kr19.83m |
| Other Expenses | kr15.84m |
| Earnings | -kr35.66m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 17, 2024
| Earnings per share (EPS) | -1.80 |
| Gross Margin | -282.92% |
| Net Profit Margin | -508.92% |
| Debt/Equity Ratio | 0% |
How did COMBI perform over the long term?
See historical performance and comparison